EVP-ABD Enhanced MRI for Evaluation Liver Disease

EVP-ABD 增强 MRI 评估肝病

• 批准号: 7157055
• 负责人: Peter R Seoane
• 金额: $ 15.32万
• 依托单位: EAGLE VISION PHARMACEUTICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-15 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7157055
• 关键词: bioimaging /biomedical imaging; contrast media; diagnosis design /evaluation; diagnosis quality /standard; disease /disorder classification; disease /disorder model; hepatitis; histopathology; image enhancement; laboratory rat; liver disorder diagnosis; magnetic resonance imaging; noninvasive diagnosis; pathologic process; pharmacokinetics; statistics /biometry; technology /technique development

DESCRIPTION (provided by applicant): Project Summary/Abstract: Hepatitis deriving from viral infection and chemical, drug or alcohol toxicity is placing a growing burden on the health care system. While initial diagnosis of hepatitis may rely on medical history, Liver Function Tests (LFT), Polymerase Chain Reaction (PCR) results, etc.; confirmation, characterization (grading and staging) and follow-up of hepatitis relies on liver biopsy as the gold standard despite significant morbidity and a small but definite risk of mortality associated with the procedure. A non-invasive test that would provide a reliable measure of the nature and magnitude of diffuse liver disease, correlating to histology and thereby reducing the dependence on periodic biopsies would meet a major unmet need. Eagle Vision Pharmaceutical Corp (EAGLE) is developing EVP-ABD, an intracellular manganese based Magnetic Resonance Imaging (MRI) contrast agent, with unique magnetic and kinetic properties. The potential for correlation between the energy dependent intracellular uptake of EVP-ABD (assessed noninvasively by MRI imaging) and liver function (assessed by histology) will be evaluated in this study. Project Narrative: The long term goal of the research is to register and commercialize EVP-ABD in the US and elsewhere as a contrast agent for diagnosis, characterization and assessing effectiveness of treatment of diffuse liver disease. If successful, EVP-ABD should reduce the dependence on serial liver biopsies by providing a noninvasive assessment of diffuse liver disease, and thus reduce the morbidity associated with the procedure.

描述（由申请人提供）：项目摘要/摘要：因病毒感染和化学，药物或酒精毒性而引起的肝炎正在对医疗保健系统造成越来越多的负担。虽然肝炎的初始诊断可能依赖病史，但肝功能测试（LFT），聚合酶链反应（PCR）结果等。确认，表征（分级和分期）以及肝炎的随访依赖于肝活检作为黄金标准，尽管发病率很高，并且与该手术相关的死亡率很小但有明确的死亡风险。一种非侵入性测试，可以可靠地衡量弥漫性肝病的性质和大小，与组织学相关，从而降低对周期活检的依赖性将满足主要的未满足需求。 Eagle Vision Pharmaceutical Corp（EAGLE）正在开发具有独特的磁性和动力学特性的基于细胞内锰的磁共振成像（MRI）对比剂EVP-ABD。本研究将评估EVP-ABD的细胞内摄取（通过MRI成像无创评估）与肝功能（通过组织学评估）之间的相关性。项目叙述：该研究的长期目标是在美国和其他地方注册和商业化EVP-ABD，以作为诊断，表征和评估弥漫性肝病治疗有效性的对比剂。如果成功，EVP-ABD应通过对弥漫性肝病的无创评估来减少对连续肝活检的依赖，从而降低与该程序相关的发病率。

项目成果

EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model.

EVP-ABD 增强 MRI 评估大鼠模型中的弥漫性肝病。

• DOI: 10.1002/jmri.21385
• 发表时间: 2008
• 期刊: Journal of magnetic resonance imaging : JMRI
• 作者: Zuo,ChunS;Seoane,PeterR;Thomsen,Morgane;Gillis,Tim;Meloni,Edward;Harnish,PhillipP;Renshaw,PerryF
• 通讯作者: Renshaw,PerryF